Targeting Siah2 as Novel Therapy for Metastatic Prostate Cancer
Abstract
The goal of this project is to develop a novel means to inhibit prostate cancer development and progression. The development of Siah1/2 inhibitors to the ubiquitin ligase Siah1/2 has been advanced by the ability to develop a Siah1/2 inhibitory peptide that effectively inhibits Siah1/2 activity, which was found to effectively attenuate the growth of prostate cancer tumors in vivo when transplanted subcutaneously or orthotopically into the prostate site. The assessment of the Siah1/2 inhibitory peptide in genetic models of mouse as in human PDX tumors is ongoing by the Partnering PIs Drs. Martin Gleave and Neil Bhowmick at the two respective sites. Parallel development of small molecule inhibitors to Siah2 is on going and will complement the work performed with the inhibitory peptide. This is a first-inclass inhibitor of the ubiquitin ligase that can be administered intravenously and that has a notable effect on prostate cancer growth in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- ADA626550
Entities
People
- Martin Gleave
Organizations
- University of British Columbia